Skip to content
Subscriber Only
Markets
Deals

Sanofi to Explore Counterbid for Actelion Amid J&J Talks

  • French drugmaker said to work with advisers to weigh options
  • Actelion said to be valued at over $27 billion in J&J offer
Video player cover image

Sanofi Said to Weigh Actelion Bid Challenging J&J

Updated on

Sanofi is considering a counterbid for Actelion Ltd., potentially challenging a move by U.S. health-care giant Johnson & Johnson to acquire Europe’s largest biotechnology firm, people familiar with the matter said.

The French drugmaker is working with advisers as it weighs its options, said the people, who asked not to be identified because the deliberations are private. Sanofi, which has informally made its interest known to Switzerland’s Actelion, hasn’t made a final decision on whether to proceed with a bid, the people said.